Latest Governance News

HMC Capital has unveiled an ambitious plan to grow its assets under management to over $50 billion within the next 3-5 years, supported by strong fundraising and diversified investment verticals. The company’s FY25 outlook remains solid, underpinned by operational growth and strategic initiatives across real estate, digital infrastructure, and energy transition.

Pancontinental Energy has responded to an ASX query about recent spikes in its share price and trading volume, confirming no undisclosed information exists and pointing to strong industry interest in its PEL 87 project.

The Acting President of the Takeovers Panel has declined an interim order to postpone FBR Limited’s upcoming Extraordinary General Meeting, keeping the scheduled vote on track.

Magnum Mining & Exploration has completed its acquisition of Palmares Estudos Geologicos LTDA, securing a significant rare earths landholding in Brazil after an extended due diligence process.

Epsilon Healthcare reports ongoing operational challenges post-voluntary administration while unveiling a new pharmacy subsidiary aimed at diversifying revenue streams and rebuilding market confidence.

Finexia Financial Group announces the resignation of Interim CEO Marc Duncan as the Board intensifies its review of credit operations and pursues ASX securities reinstatement.

A shareholder has lodged an application with the Takeovers Panel challenging FBR Limited’s upcoming extraordinary general meeting resolutions related to significant share placements and funding arrangements with Fidelity International.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Pact Group Holdings has received conditional approval from the ASX for its voluntary delisting, pending shareholder endorsement at an upcoming extraordinary general meeting scheduled for 12 June 2025.

Citigold Corporation Limited has had its trading suspension lifted immediately following the submission of its reissued half year financial report and responses to ASX compliance queries.

Citigold Corporation Limited has faced intense ASX scrutiny following an adverse auditor opinion on its half-year financials, centering on a $20 million impairment of exploration assets. The company defends its valuation approach despite funding uncertainties and regulatory questions.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.